Insider filing · GKOS
Tomas Navratil
CHIEF DEVELOPMENT OFFICER
profile →
Glaukos Corporation
GKOS · Healthcare · 34 filings in 24 months
ticker →
Tomas Navratil sold $2.5M of Glaukos (GKOS)
Executed Aug 28, disclosed Sep 1, 4 days later.
Value, as filed
$2.5M
13,734 sh across 2 lots
Executed
Aug 28
the trade date, as filed
Disclosed
Sep 1
4 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
TNTomas Navratil (CHIEF DEVELOPMENT OFFICER) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in Glaukos Corporation (GKOS). The largest single filing was $10.6M of GKOS (44,436 sh across 4 lots, as filed), executed Oct 30.
The name
GKOSHealthcare · Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Tomas Navratil in GKOS
GKOSSALE
Glaukos Corporation
$10.6M44,436 sh across 4 lots
Exec Oct 30
Filed Nov 3 · 9:45 PM ET GKOSSALE Glaukos Corporation $146K
888 sh × $163.93
Exec Oct 5
Filed Oct 7 · 7:07 PM ET GKOSSALE Glaukos Corporation $168K
1,083 sh × $154.88
Exec Sep 25
Filed Sep 28 · 6:23 PM ET GKOSSALE Glaukos Corporation $201K
1,537 sh × $130.68
Exec Jun 16
Filed Jun 18 · 5:30 PM ET GKOSSALE Glaukos Corporation $144K
1,237 sh × $116.72
Exec Apr 10
Filed Apr 14 · 5:30 PM ET GKOSSALE Glaukos Corporation $454K
5,142 sh across 2 lots
Exec Sep 11 2025
Filed Sep 12 2025 · 5:30 PM ET GKOSSALE Glaukos Corporation $503K
3,416 sh × $147.14
Exec Feb 14 2025
Filed Feb 19 2025 · 5:30 PM ET